Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Idiopathic Intracranial Hypertension
NCT06361823Phase 3Not yet recruiting
- Sponsor
- Capital Medical University
- Start
- May 2024
- Primary completion
- Dec 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of semaglutide in idiopathic intracranial hypertension (IIH), sponsored by Capital Medical University. Planned start May 2024; status: not yet recruiting.
02
Drugs
03
Conditions
idiopathic intracranial hypertension (IIH)
Beyond the preview
Go deeper on NCT06361823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06361823.